Medindia

X

Turing’s CEO in Trouble for Planning to Overprice a Free Drug in the US

by Reshma Anand on  December 15, 2015 at 3:45 PM Corporate News   - G J E 4
The most hated CEO in the United States is again planning to increase the price of a drug used to treat Chagas disease in the Latin America.
Turing’s CEO in Trouble for Planning to Overprice a Free Drug in the US
Turing’s CEO in Trouble for Planning to Overprice a Free Drug in the US
Advertisement

Chagas disease also called as Trypanosomiasis is caused through a bite of a bug leading to heart problems that could turn fatal. According to WHO the disease affects 300,000 Americans and about 6 to 7 million people worldwide.

‘Turing Pharmaceuticals CEO gets under fire for planning to overprice the already available common drug for treating Chagas disease in the US. But the drug is already available for free in Latin America.’
Advertisement
Martin Shrkeli, CEO of Turing Pharmaceuticals has also taken control of KaloBios Pharmaceuticals, which owns the generic version of the Chagas drug, benznidazole. The drug has been approved by the FDA for use in the Latin american region but not in the United States.

Taking this as an advantage, Shrkeli has reportedly planned to increase the price of the drug in the USA. He has told his company to fast-track the approval of this drug so they can be entitled to have exclusive rights to it within the next five years. By then, the drug could be selling at least $60,000 per treatment, a far cry from $50 to $100 plan given to Latin America over the course of two months.

The drug has a 100% cure rate especially when the patient is treated during the early stages of the disease and is also available for free in acute cases.

Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All